Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Offer practical starter options for 2024, including how to evaluate coins, wallets, and purchasing steps for beginners.
23,003 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
BuildersUpdate launched a pay-on-performance marketing model, charging a $750 fee per home only when a sale closes, a...
Investors are watching whether NVIDIA back business China could unlock a new revenue stream. This analysis covers sce...
Three dividend aristocrats have boosted payouts for a combined 187 years, delivering steady passive income for invest...
AI-powered platforms are cutting construction draw timelines dramatically, compressing review cycles from days to hou...
A former antitrust prosecutor who helped litigate the JetBlue-Spirit merger shares lessons for future airline regulat...
Geopolitical tensions push fuel costs higher, prompting DoorDash to fund more than $50 million in gas-price relief fo...
AFC Gamma investors are watching the Q1 2026 earnings call closely. This guide breaks down what to expect, how to rea...
Cloudflare's first-quarter 2026 results set the stage for a dynamic year. This analysis breaks down what worked, what...
Raymond James just upgraded Fastly to Outperform with a $23 price target after a sharp one-day drop, pointing to AI-d...
A new voter poll shows broad demand for federal action to reduce housing costs, with cross‑party support for quick pa...
Trex's 2026 earnings narrative is shaping how investors view the decking market. This guide breaks down Q1 signals, w...